HeadInvest LLC’s ImmuCell ICCC Stock Holding History

HeadInvest LLC’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,118	Closed	-$16.3K	–	437
2023 Q3	$16.3K	Buy	+3,118	New	+$15.8K	﹤0.01%	494

Other funds holding ICCC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OMC

Overbrook Management Corp New York $663M AUM 35.04% 1-Year Est. Return

HeadInvest LLC's ICCC Position: Q4 2023 in Review

HeadInvest LLC sold out of ImmuCell (ICCC) in Q4 2023, closing a stake of 3,118 shares — an estimated $16.3K sold.

HeadInvest LLC first reported a position in ICCC in Q3 2023 and held it in 1 quarter. The position peaked at $16.3K in Q3 2023. 28 funds tracked by Wall St. Rank hold ICCC as of Q4 2023.

HeadInvest LLC reported no remaining ImmuCell position as of Q4 2023 after selling out during the quarter.
HeadInvest LLC sold 3,118 ImmuCell shares in Q4 2023, an estimated $16.3K.
HeadInvest LLC first reported a position in ImmuCell in Q3 2023 and held it in 1 quarter.
HeadInvest LLC's ImmuCell position peaked at $16.3K in Q3 2023.
28 funds tracked by Wall St. Rank held ImmuCell as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.